SCHEMBL1749025

SCHEMBL1749025

Fc1cnc2[nH]ccc2c1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 3/20 0.62
AXL P30530 2/20 0.62
NUDT1 P36639 3/20 0.47
DAO P14920 1/20 0.45
DDO Q99489 1/20 0.45
RPS6KA3 P51812 2/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
TTBK1 Q5TCY1 4/20 0.39
TTBK2 Q6IQ55 4/20 0.39
TRPA1 O75762 4/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
NTRK1 P04629 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29431105 1.00 PRKCI (0.62) PRKCIAXLNUDT1DAODDO
Pyridine SCHEMBL3094623 0.89 PRKCI (0.51) PRKCIAXLNUDT1DAODDO
SCHEMBL1356886 0.80 PRKCI (0.67) PRKCIAXLNUDT1RPS6KA3TTBK1
SCHEMBL1467759 0.80 NUDT1 (0.50) PRKCIAXLNUDT1RPS6KA3MKNK1
SCHEMBL29660498 0.80 NUDT1 (0.50) PRKCIAXLNUDT1RPS6KA3MKNK1
SCHEMBL2974630 0.77 PRKCI (0.62) PRKCIAXLNUDT1MKNK1MKNK2
SCHEMBL1564932 0.77 PRKCI (0.62) PRKCIAXLNUDT1RPS6KA3TTBK1
SCHEMBL1468832 0.77 PRKCI (0.62) PRKCIAXLNUDT1RPS6KA3TTBK1
SCHEMBL12561934 0.77 PRKCI (1.00) PRKCIAXLNUDT1RPS6KA3TTBK1
SCHEMBL30084334 0.77 PRKCI (0.62) PRKCIAXLNUDT1RPS6KA3TTBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087613-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS, PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2026-04-30 WO disclosed
CN-121800777-A Green and efficient synthesis method of high-purity 4-chloro-5-fluoro-7-azaindole 苏州艾缇克药物化学有限公司 2026-04-07 CN disclosed
CN-121800777-A Green and efficient synthesis method of high-purity 4-chloro-5-fluoro-7-azaindole 苏州艾缇克药物化学有限公司 2026-04-07 CN disclosed
US-20260028345-A1 BTK DEGRADER AND USE THEREOF ASCENTAGE PHARMA SUZHOU CO LTD (CN) 2026-01-29 US disclosed
US-20260028346-A1 BTK DEGRADER AND USE THEREOF ASCENTAGE PHARMA SUZHOU CO LTD (CN) 2026-01-29 US disclosed
WO-2025096463-A1 PLK4 MODULATORS VIBLIOME THERAPEUTICS, LLC (US) 2025-05-08 WO disclosed
EP-4234558-A1 PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. (CN) 2023-08-30 EP disclosed
EP-3152210-B1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2023-07-05 EP disclosed
EP-3152210-B1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2023-07-05 EP disclosed
WO-2022187518-A1 SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Ikena Oncology, Inc. (US) 2022-09-09 WO disclosed
US-20090264399-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-10-22 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
CN-101223168-A Heterocyclic JANUS kinase 3 inhibitors ASTELLAS PHARMA INC (JP) 2008-07-16 CN disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
CN-101052642-A Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors AVENTIS PHARMA SA (FR) 2007-10-10 CN disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 EP disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed
CN-1950083-A Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA SA (FR) 2007-04-18 CN disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028345-A1 BTK DEGRADER AND USE THEREOF BTK, SYK, TEC PRKCI 518/4885AXL 157/4885NUDT1 4677/4885
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 PRKCI 209/4885AXL 636/4885NUDT1 1898/4885
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 PRKCI 168/4885AXL 290/4885NUDT1 2531/4885
US-20260028346-A1 BTK DEGRADER AND USE THEREOF BTK, SYK, LYN PRKCI 480/4885AXL 123/4885NUDT1 4656/4885
US-20090264399-A1 HETEROCYCLIC JANUS KINASE 3 INHIBITORS JAK3, JAK2, JAK1 PRKCI 179/4885AXL 313/4885NUDT1 3092/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 PRKCI 168/4885AXL 290/4885NUDT1 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.